首頁 > 市場調查報告書 > 醫療設備

生技設備生物標記

市場調查報告書

商品編碼

1457957

細胞表面標記檢測的全球市場：市場規模和佔有率分析（依產品和應用）、產業收入估算和需求預測（截至2030年）

Cell Surface Marker Detection Market Share Analysis by Product, Application - Global Industry Revenue Estimation and Demand Forecast to 2030

出版日期: 2024年02月01日 | 出版商:

Prescient & Strategic Intelligence | 英文 270 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2023年全球細胞表面標記檢測市場規模估計為55.055億美元，2030年將達到94.274億美元，推動預測期內成長率為8.1%。該行業的推動因素包括對精準醫療的需求不斷增長、體外診斷接受度的提高以及提高吞吐量和自動化率的技術進步。

流式細胞儀設備引領市場

流式細胞儀設備佔比最大，2023年將達35%。這主要是因為該方法可以測量同一樣本中的大量參數，並且可以在幾秒鐘內收集數百萬個細胞的數據。

藥物發現和研究領域成長最快的應用

到2030年，藥物發現和研究領域將以8.4%的速度成為業界成長最快的領域。其主要原因是慢性病的增加以及隨之而來的醫療費用的急劇增加。

據一份報告稱，2000年，美國有超過1.2億人患有至少一種慢性病。直到2030年，這個數字每年都會增加1%以上。

因此，2000年至2030年間，北美慢性病患者人數將增加約40%，即約5,000萬人。

北美地區處於領先地位

北美是該市場的區域領導者，到 2023 年將佔 55% 的佔有率。這是由於技術進步、老年人口不斷增長以及慢性病盛行率不斷上升。

亞太地區將成長最快

預計到本十年末，亞太地區將經歷最快的成長。這主要是由於老年人數量的增加以及藥物發現和研究的最新進展，特別是在基因治療方面。該行業的發展也受到心血管疾病、糖尿病和癌症患者數量不斷增加的推動。

在印度，受癌症影響的人數預計將從 2021 年的約 2,700 萬人增加到 2025 年的約 3,000 萬人。

本報告分析了全球細胞表面標記檢測市場，提供了市場的基本結構、最新情況、主要促進和抑制因素以及全球、依地區和主要國家的市場規模前景（價值基礎，2017年） -2030），依產品和應用劃分的詳細趨勢、當前市場競爭狀況以及主要公司簡介。

The size of the cell surface marker detection market was USD 5,505.5 million in 2023, and it will touch USD 9,427.4 million by 2030, propelling at a rate of 8.1% during the projection period. The industry is powered by the increase in the requirement for precision medicine, the increase in the acceptance of in vitro diagnostics, and tech advancements that enhance throughput and the automation rate.

Drivers of the Industry

Cell surface markers help in recognizing high-risk patients precisely, enhancing the accuracy of the diagnosis, progressing follow-up policies for people, estimating susceptibility to targeted therapy or immunotherapy, and predicting prognostic outcomes.

Precision medicine is used in the treatment of many subspecialties, mostly in cancer and inherited diseases, for both diagnosis and treatment, using next-gen sequencing.

Precision medicine reduces the cost of care and advances the overall health of people through the use of pharmacogenomics, which uses patient data to create effective and safe plans for the medication of patients.

Precision medicine is a cutting-edge method of altering the approaches to disease prevention and treatment.

It will allow doctors and researchers to predict more precisely the most appropriate treatment with information on the molecular and genetic makeup of the patient, environment, and lifestyle.

Flow Cytometry Instruments Led the Market

The flow cytometry instruments had the largest share, of 35%, in 2023. This is principally because this method can measure numerous parameters in the same sample and collect data from millions of cells within seconds.

Moreover, with this method, any non-uniformity in a uniform cell populace is detected, and it also eliminates all the dead cells or debris when the final data is provided.

Drug Discovery and Research is the Fastest Growing Application

The drug discovery and research category will grow the fastest in the industry, with a rate of 8.4%, by 2030. This is mostly because of the increasing occurrence of chronic ailments and the resulting surge in healthcare spending.

As per a report, in 2000, in the U.S., people with over one chronic condition were over 120 million. This number will increase by over 1% every year till 2030.

Hence, between 2000 and 2030, the number of people in North America with chronic conditions will surge by about 40% or around 50 million individuals.

North America is the Regional Leader

North America was the regional leader of the market, with a 55% share, in 2023, because of the growing count of tech progressions, surging elderly population, and growing incidence of chronic diseases.

In the U.S., there is an increase in the count of citizens aged 65 and more. This share of the elderly people in the total populace will rise to about 24% by 2060 from 15% in 2016.

The aging population is more susceptible to chronic ailments, for example, cardiac conditions, gastrointestinal issues, and cancer. Moreover, the U.S. is the 5th globally for age-standardized rates for all cancers.

APAC To Experience Fastest Growth

APAC will have the fastest growth by the end of this decade. This is mostly due to the increasing number of elderly people and recent advances in drug discovery and research procedures, particularly in gene therapy. The rising populace of patients with CVDs, diabetes, and cancer is also powering the industry.

In India, the number of people suffering from cancer will increase to about 30 million in 2025 from approximately 27 million in 2021.

Chapter 1. Research Scope

1.1. Research Objectives
1.2. Market Definition
1.3. Analysis Period
1.4. Market Size Breakdown by Segments
- 1.4.1. Market size breakdown, by product
- 1.4.2. Market size breakdown, by application
- 1.4.3. Market size breakdown, by region
- 1.4.4. Market size breakdown, by country
1.5. Market Data Reporting Unit
- 1.5.1. Value
1.6. Key Stakeholders

Chapter 2. Research Methodology

2.1. Secondary Research
- 2.1.1. Paid
- 2.1.2. Unpaid
- 2.1.3. P&S Intelligence database
2.2. Primary Research
2.3. Market Size Estimation
2.4. Data Triangulation
2.5. Currency Conversion Rates
2.6. Assumptions for the Study
2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

5.1. Market Dynamics
- 5.1.1. Trends
- 5.1.2. Drivers
- 5.1.3. Restraints/challenges
- 5.1.4. Impact analysis of drivers/restraints
5.2. Impact of COVID-19
5.3. Porter's Five Forces Analysis
- 5.3.1. Bargaining power of buyers
- 5.3.2. Bargaining power of suppliers
- 5.3.3. Threat of new entrants
- 5.3.4. Intensity of rivalry
- 5.3.5. Threat of substitutes

Chapter 6. Global Market

6.1. Overview
6.2. Market Revenue, by Product (2017-2030)
6.3. Market Revenue, by Application (2017-2030)
6.4. Market Revenue, by Region (2017-2030)

Chapter 7. North America Market

7.1. Overview
7.2. Market Revenue, by Product (2017-2030)
7.3. Market Revenue, by Application (2017-2030)
7.4. Market Revenue, by Country (2017-2030)

Chapter 8. Europe Market

8.1. Overview
8.2. Market Revenue, by Product (2017-2030)
8.3. Market Revenue, by Application (2017-2030)
8.4. Market Revenue, by Country (2017-2030)

Chapter 9. APAC Market

9.1. Overview
9.2. Market Revenue, by Product (2017-2030)
9.3. Market Revenue, by Application (2017-2030)
9.4. Market Revenue, by Country (2017-2030)

Chapter 10. LATAM Market

10.1. Overview
10.2. Market Revenue, by Product (2017-2030)
10.3. Market Revenue, by Application (2017-2030)
10.4. Market Revenue, by Country (2017-2030)

Chapter 11. MEA Market

11.1. Overview
11.2. Market Revenue, by Product (2017-2030)
11.3. Market Revenue, by Application (2017-2030)
11.4. Market Revenue, by Country (2017-2030)

Chapter 12. U.S. Market

12.1. Overview
12.2. Market Revenue, by Product (2017-2030)
12.3. Market Revenue, by Application (2017-2030)

Chapter 13. Canada Market

13.1. Overview
13.2. Market Revenue, by Product (2017-2030)
13.3. Market Revenue, by Application (2017-2030)

Chapter 14. Germany Market

14.1. Overview
14.2. Market Revenue, by Product (2017-2030)
14.3. Market Revenue, by Application (2017-2030)

Chapter 15. France Market

15.1. Overview
15.2. Market Revenue, by Product (2017-2030)
15.3. Market Revenue, by Application (2017-2030)

Chapter 16. U.K. Market

16.1. Overview
16.2. Market Revenue, by Product (2017-2030)
16.3. Market Revenue, by Application (2017-2030)

Chapter 17. Italy Market

17.1. Overview
17.2. Market Revenue, by Product (2017-2030)
17.3. Market Revenue, by Application (2017-2030)

Chapter 18. Spain Market

18.1. Overview
18.2. Market Revenue, by Product (2017-2030)
18.3. Market Revenue, by Application (2017-2030)

Chapter 19. Japan Market

19.1. Overview
19.2. Market Revenue, by Product (2017-2030)
19.3. Market Revenue, by Application (2017-2030)

Chapter 20. China Market

20.1. Overview
20.2. Market Revenue, by Product (2017-2030)
20.3. Market Revenue, by Application (2017-2030)

Chapter 21. India Market

21.1. Overview
21.2. Market Revenue, by Product (2017-2030)
21.3. Market Revenue, by Application (2017-2030)

Chapter 22. Australia Market

22.1. Overview
22.2. Market Revenue, by Product (2017-2030)
22.3. Market Revenue, by Application (2017-2030)

Chapter 23. South Korea Market

23.1. Overview
23.2. Market Revenue, by Product (2017-2030)
23.3. Market Revenue, by Application (2017-2030)

Chapter 24. Brazil Market

24.1. Overview
24.2. Market Revenue, by Product (2017-2030)
24.3. Market Revenue, by Application (2017-2030)

Chapter 25. Mexico Market

25.1. Overview
25.2. Market Revenue, by Product (2017-2030)
25.3. Market Revenue, by Application (2017-2030)

Chapter 26. Saudi Arabia Market

26.1. Overview
26.2. Market Revenue, by Product (2017-2030)
26.3. Market Revenue, by Application (2017-2030)

Chapter 27. South Africa Market

27.1. Overview
27.2. Market Revenue, by Product (2017-2030)
27.3. Market Revenue, by Application (2017-2030)

Chapter 28. U.A.E. Market

28.1. Overview
28.2. Market Revenue, by Product (2017-2030)
28.3. Market Revenue, by Application (2017-2030)

Chapter 29. Competitive Landscape

29.1. List of Market Players and their Offerings
29.2. Competitive Benchmarking of Key Players
29.3. Product Benchmarking of Key Players
29.4. Recent Strategic Developments

Chapter 30. Company Profiles

30.1. Abbott Laboratories
- 30.1.1. Business overview
- 30.1.2. Product and service offerings
- 30.1.3. Key financial summary
30.2. Becton, Dickinson and Company
- 30.2.1. Business overview
- 30.2.2. Product and service offerings
- 30.2.3. Key financial summary
30.3. Nihon Kohden Corporation
- 30.3.1. Business overview
- 30.3.2. Product and service offerings
- 30.3.3. Key financial summary
30.4. Thermo Fisher Scientific Inc.
- 30.4.1. Business overview
- 30.4.2. Product and service offerings
- 30.4.3. Key financial summary
30.5. Sysmex Corporation
- 30.5.1. Business overview
- 30.5.2. Product and service offerings
- 30.5.3. Key financial summary
30.6. Janssen Diagnostics Inc.
- 30.6.1. Business overview
- 30.6.2. Product and service offerings
- 30.6.3. Key financial summary
30.7. Grifols SA
- 30.7.1. Business overview
- 30.7.2. Product and service offerings
- 30.7.3. Key financial summary
30.8. Siemens Healthcare
- 30.8.1. Business overview
- 30.8.2. Product and service offerings
- 30.8.3. Key financial summary
30.9. BioRad Laboratories Inc.
- 30.9.1. Business overview
- 30.9.2. Product and service offerings
- 30.9.3. Key financial summary
30.10. F. Hoffmann-La Roche Ltd.
- 30.10.1. Business overview
- 30.10.2. Product and service offerings
- 30.10.3. Key financial summary